Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Reaches New 12-Month High at $31.28

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF)’s share price hit a new 52-week high on Monday . The stock traded as high as $31.28 and last traded at $31.28, with a volume of 0 shares traded. The stock had previously closed at $31.28.

Swedish Orphan Biovitrum AB (publ) Stock Performance

The firm has a 50 day simple moving average of $26.75 and a 200-day simple moving average of $26.05. The company has a market cap of $9.23 billion, a price-to-earnings ratio of 52.13 and a beta of 0.59. The company has a debt-to-equity ratio of 0.32, a current ratio of 0.71 and a quick ratio of 0.50.

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) last posted its quarterly earnings data on Tuesday, July 16th. The company reported $0.07 earnings per share (EPS) for the quarter. The firm had revenue of $509.05 million for the quarter. Swedish Orphan Biovitrum AB (publ) had a return on equity of 7.00% and a net margin of 9.10%.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.